TY - JOUR
T1 - Predictive factors for long-term engraftment of autologous blood stem cells
AU - Duggan, P. R.
AU - Guo, D.
AU - Luider, J.
AU - Auer, I.
AU - Klassen, J.
AU - Chaudhry, A.
AU - Morris, D.
AU - Glück, S.
AU - Brown, C. B.
AU - Russell, J. A.
AU - Stewart, D. A.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Data from 170 consecutive patients aged 19-66 years (median age 46 years) who underwent unmanipulated autologous blood stem cell transplant (ASCT) were analyzed to determine if total CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+90+, CD34+33-, CD34+38-D, CD34+38-DR-), peripheral blood CD34+ cell (PBCD34+) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or reinduction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n =4). Of the remaining 136 patients, 46% had low WBC (<4 × 109/I), 41% low platelets (<150 × 109/I), and 34% low hemoglobin (<120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34+ cell dose/kg and the PBCD34+ count correlated with 6 month blood counts better than any subset of CD34+ cells or any clinical factor. The PBCD34+ count was overall a stronger predictor of 6 month blood counts than was the total CD34+ cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34+ cells and clinical factors are inferior to the total CD34+ cell dose/kg and PBCD34+ count in predicting 6 month blood counts following ASCT.
AB - Data from 170 consecutive patients aged 19-66 years (median age 46 years) who underwent unmanipulated autologous blood stem cell transplant (ASCT) were analyzed to determine if total CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+90+, CD34+33-, CD34+38-D, CD34+38-DR-), peripheral blood CD34+ cell (PBCD34+) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or reinduction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n =4). Of the remaining 136 patients, 46% had low WBC (<4 × 109/I), 41% low platelets (<150 × 109/I), and 34% low hemoglobin (<120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34+ cell dose/kg and the PBCD34+ count correlated with 6 month blood counts better than any subset of CD34+ cells or any clinical factor. The PBCD34+ count was overall a stronger predictor of 6 month blood counts than was the total CD34+ cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34+ cells and clinical factors are inferior to the total CD34+ cell dose/kg and PBCD34+ count in predicting 6 month blood counts following ASCT.
KW - Autologous
KW - CD34 subsets
KW - Hematopoietic stem cell transplantation
KW - Long-term engraftment
UR - http://www.scopus.com/inward/record.url?scp=17744400478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17744400478&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1702708
DO - 10.1038/sj.bmt.1702708
M3 - Article
C2 - 11223969
AN - SCOPUS:17744400478
VL - 26
SP - 1299
EP - 1304
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 12
ER -